Please assess the completion status of the following clinical trial:

Trial Title: Glutamatergic Modulation of Cocaine-related Deficits

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Active free-base cocaine dependence (at least 4 days of use over the past month, with at least 1 use per week); if the participant uses through another route (IN, IV), then the FB route is dominant (\> 80% of occasions).~2. Physically healthy~3. No adverse reactions to study medications~4. 21-52 years of age~5. Normal body weight~6. Responsive to drug cues~7. Capacity to consent~Exclusion Criteria:~1. Seeking treatment or abstinence~2. DSM IV criteria for substance dependence (other than methamphetamine, cocaine, cannabis, or nicotine), or DSM IV criteria for abuse of ketamine or lorazepam~3. DSM-IV criteria for other Axis I psychiatric illness that may make participation hazardous such as schizophrenia, schizoaffective disorder, psychosis NOS, MDD, psychosis secondary to substances, or bipolar disorder~4. Delirium, Dementia, Amnesia, Cognitive Disorders, or dissociative disorders~5. Current suicide risk or a history of suicide attempt within the past 2 years~6. Current use of prescribed psychotropic medication~7. Pregnancy, nursing, or had a baby within the past 6 mo.~8. Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.~9. Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (\>140/90), anemia, active hepatitis or other liver disease, or diabetes~10. Bad reaction/experience with prior exposure to ketamine or lorazepam~11. History of significant violence~12. First degree relative with a psychotic disorder

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 52 Years
- Healthy Volunteers: f

Study Arms:
- K1 (Type: EXPERIMENTAL): Ketamine 0.41 mg/kg infused over 52 min (K1)
- K2 (Type: EXPERIMENTAL): Ketamine 0.71 mg/kg infused over 52 min (K2)
- LZP (Type: EXPERIMENTAL): Lorazepam 2 mg infused over 52 minutes (LZP)

Based on this trial design, predict the completion outcome and termination type (if applicable).